Abstract: Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study
Source: Journal of Viral Hepatitis, https://doi.org/10.1111/jvh.12837
Summary: This study evaluated liver cancer in British Columbia, Canada (58,487 patients), New South Wales, Australia (84,529 pts), and Scotland (31,924 pts). The time periods studied were 1995-2011/2012/2013.
A little over 1% of the people in the countries studied had an HCV-related liver cancer diagnosis. Since the mid-2000’s the prevalence of liver cancer has slightly increased in the regions. Liver cancer rates either stablized or slightly increased in the era of interferon-based therapy era. Older age was a predictor of the development of liver cancer. Finally, the authors noted that earlier and improved screening for liver cancer and the introduction of direct-acting antiviral medications should reduce HCV-related liver cancer rates in the coming years.
Abstract: Hepatitis C care in the Department of Veterans Affairs: Building a foundation for success – P. S. Belperio, et. al.
Source: Infect Dis Clin N Am 32 (2018) 281–292
Summary: The Veterans Affairs (VA) is the largest medical provider for patients infected with hepatitis C in the United States. The VA estimates that 8.4% U.S. of veterans are infected with hepatitis C and have diagnosed 90% of veterans. An estimated 8,000-10,000 veterans remain undiagnosed. HCV treatment in the VA is available through an innovative approach that uses clinical pharmacists, nurse practitioners, physician assistants, video telehealth medicine and various electronic technologies. Maximum patient co-pay costs are $33.00 for a 12-week supply. The co-pay cost may be waived depending on the patient’s financial situation. As of December 2017, the VA has treated 100,000 veterans infected with hepatitis C.
Article: Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis – P. Cacoub, et. al.
Source: Gut 2018; – Published Online First: 05 Jun 2018. doi: 10.1136/gutjnl-2018-316578
Summary: A meta-analysis of 48 studies found that achieving a cure reduced deaths from extrahepatic manifestations. Also, being cured was associated with a higher remission in patients with cryoglobulinemia vasculitis and malignant B-cell lymphoproliferative diseases. Furthermore, achieving a cure was associated with reduced insulin resistance and a significant effect on the incidence of diabetes. However, the authors commented that there needed to be higher quality data and longer follow-up periods.
Abstract: Viral hepatitis screening in transgender patients undergoing gender identity hormonal therapy – N. Mangla, et. al.
Source: Eur J Gastroenterol Hepatol. 2017 Nov;29(11):1215-1218. doi: 10.1097/MEG.0000000000000950.
Summary: A review of records from 2012 to 2015 in an LGBTQ-friendly clinic in New York City was conducted to understand the screening practices and prevalence of viral hepatitis. Approximately 13% of patients were screened. Screening rates were 27% for hepatitis C (HCV), 22% for hepatitis B (HBV) and 20% for hepatitis A (HAV). HAV screening in female to male were 28%; male to female were 16%. HBV screening in female to male was 30%; male to female was 18%. HCV screening in female to male was 31%; male to female was 17%.
The prevalence of HCV, HBV, and HIV in female to male was 0%, 0%, and 0.44% and male to female was 1.78%, .0890%, and 1.78%. The percentage of patient’s immune to HAV in male to female and female to male ranged from 54% to 58%. The authors commented that there was a lack of hepatitis screening in the transgender population. The authors also noted that there are no guidelines for screening transgender people.
Share This Page